Patient data
| Patient no. . | Age, y/sex . | Previous treatment . | TT, mo . | Basal platelets ×109/L/Hb, g/dL . | Best response . | Time to PR/CR, wk . | Maximum platelets ×109/L/Hb, g/dL . | Duration of response, wk . | Current status . | Follow-up, wk . |
|---|---|---|---|---|---|---|---|---|---|---|
| ITP1 | 26/F | P, S, D | 73 | 20 | PR | 1/− | 105 | 16 | Relapse | 98 |
| ITP2 | 16/F | P, D | 52 | 17 | CR | 1/63 | 308 | 30 | Relapse | 104 |
| ITP3 | 71/F | P, Cy, D | 178 | 36 | PR | 1/− | 88 | 82 | PR | 83 |
| ITP4 | 33/F | P, IVIG, D | 3 | 11 | CR | 1/1 | 395 | 85 | CR | 86 |
| ITP5 | 20/F | P | 7 | 66 | CR | 1/4 | 256 | 46 | PR | 50 |
| ITP6 | 59/M | P, IVIG | 4 | 4 | CR | 1/1 | 156 | 24 | Relapse | 54 |
| ITP7 | 25/F | P, MP | 101 | 4 | CR | 1/5 | 259 | 65 | CR | 70 |
| ITP8 | 61/M | P | 37 | 35 | PR | 1/− | 75 | 37 | PR | 38 |
| ITP9 | 43/M | Dex, D | 59 | 8 | PR | 1/− | 108 | 39 | PR | 40 |
| ITP10 | 18/F | P, IVIG, D, rituximab | 39 | 26 | PR | 1/− | 76 | 88 | PR | 89 |
| ITP11 | 17/M | IVIG, P | 8 | 10 | PR | 1/− | 130 | 54 | Relapse | 64 |
| AIHA1 | 60/F | P, D, S, IVIG | 117 | 6.3 | CR | −/8 | 13.2 | 46 | CR | 54 |
| AIHA2 | 71/F | P, D, S | 52 | 10.5 | CR | 1/3 | 13.8 | 46 | Relapse | 63 |
| AIHA3 | 31/F | P, S, D | 169 | 9.9 | CR | −/20 | 12.7 | 47 | Relapse | 80 |
| AIHA4* | 31/M | P, Cy | 13 | 15.2 | CR | −/8 | 16.2 | 89 | CR | 97 |
| AIHA5 | 67/M | P | 12 | 12.1 | PR | 31/− | 12.4 | 66 | Relapse | 91 |
| AIHA6 | 26/F | P | 23 | 8.4 | PR | 6/− | 10.9 | 22 | Relapse | 38 |
| AIHA7 | 57/M | P | 11 | 6.4 | CR | 2/4 | 14.2 | 33 | CR | 37 |
| AIHA8† | 54/F | P, D, alemtuzumab | 45 | 8.7 | CR | 3/5 | 13.5 | 22 | Relapse | 79 |
| Patient no. . | Age, y/sex . | Previous treatment . | TT, mo . | Basal platelets ×109/L/Hb, g/dL . | Best response . | Time to PR/CR, wk . | Maximum platelets ×109/L/Hb, g/dL . | Duration of response, wk . | Current status . | Follow-up, wk . |
|---|---|---|---|---|---|---|---|---|---|---|
| ITP1 | 26/F | P, S, D | 73 | 20 | PR | 1/− | 105 | 16 | Relapse | 98 |
| ITP2 | 16/F | P, D | 52 | 17 | CR | 1/63 | 308 | 30 | Relapse | 104 |
| ITP3 | 71/F | P, Cy, D | 178 | 36 | PR | 1/− | 88 | 82 | PR | 83 |
| ITP4 | 33/F | P, IVIG, D | 3 | 11 | CR | 1/1 | 395 | 85 | CR | 86 |
| ITP5 | 20/F | P | 7 | 66 | CR | 1/4 | 256 | 46 | PR | 50 |
| ITP6 | 59/M | P, IVIG | 4 | 4 | CR | 1/1 | 156 | 24 | Relapse | 54 |
| ITP7 | 25/F | P, MP | 101 | 4 | CR | 1/5 | 259 | 65 | CR | 70 |
| ITP8 | 61/M | P | 37 | 35 | PR | 1/− | 75 | 37 | PR | 38 |
| ITP9 | 43/M | Dex, D | 59 | 8 | PR | 1/− | 108 | 39 | PR | 40 |
| ITP10 | 18/F | P, IVIG, D, rituximab | 39 | 26 | PR | 1/− | 76 | 88 | PR | 89 |
| ITP11 | 17/M | IVIG, P | 8 | 10 | PR | 1/− | 130 | 54 | Relapse | 64 |
| AIHA1 | 60/F | P, D, S, IVIG | 117 | 6.3 | CR | −/8 | 13.2 | 46 | CR | 54 |
| AIHA2 | 71/F | P, D, S | 52 | 10.5 | CR | 1/3 | 13.8 | 46 | Relapse | 63 |
| AIHA3 | 31/F | P, S, D | 169 | 9.9 | CR | −/20 | 12.7 | 47 | Relapse | 80 |
| AIHA4* | 31/M | P, Cy | 13 | 15.2 | CR | −/8 | 16.2 | 89 | CR | 97 |
| AIHA5 | 67/M | P | 12 | 12.1 | PR | 31/− | 12.4 | 66 | Relapse | 91 |
| AIHA6 | 26/F | P | 23 | 8.4 | PR | 6/− | 10.9 | 22 | Relapse | 38 |
| AIHA7 | 57/M | P | 11 | 6.4 | CR | 2/4 | 14.2 | 33 | CR | 37 |
| AIHA8† | 54/F | P, D, alemtuzumab | 45 | 8.7 | CR | 3/5 | 13.5 | 22 | Relapse | 79 |
TT indicates time to treatment; PR, partial response; CR, complete response; P, prednisone; S, splenectomy; D, danazol; Cy, cyclophosphamide; IVIG, intravenous immunoglobulin; MP, methylprednisolone; and Dex, dexamethasone.
Considered refractory to therapy because of intense signs of hemolysis despite high-dose steroids.
Patient retreated, attaining a second response maintained for 28 weeks.